Cost Utility Analysis of Erythropoietin for Anemia Treatment in Hemodialysis Patients (CUAEPO)
To study the cost utility analysis of Erythropoietin (EPO) for maintaining the different hemoglobin (Hb) target levels in anemic hemodialysis patient in routine clinical practice.
Chronic Renal Failure
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Cost Utility Analysis of Erythropoietin for Anemia Treatment in Hemodialysis Patients at University Hospital in Thailand|
- The utility scores of hemodialysis (HD) patients who use EPO to maintain the Hb target level. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
- Cost of HD patients who use EPO to maintain the Hb target level. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
- The incremental cost-effectiveness ratio (calculated as the ratio between the incremental differences in costs and QALYs associated with 2 alternative treatments) of EPO at the different Hb target levels in HD patients in routine clinical practice. [ Time Frame: lifetime horizon (Economic evaluation term) ] [ Designated as safety issue: Yes ]
|Study Start Date:||November 2009|
|Estimated Study Completion Date:||May 2010|
|Estimated Primary Completion Date:||January 2010 (Final data collection date for primary outcome measure)|
In Thailand, the studies that were conducted to find the most useful target Hb have not included the cost effectiveness and/or cost utility analyses. The level at which quality of life is maximized and risk is minimized would be the optimal target. Dialysis patients carry higher risk of death than general population. Anemia is the common complication found in dialysis patients that could lead to mortality. Risk of anemia is occurred in HD patients more than CAPD patients because blood loss is less marked and residual renal function maybe better preserved in patients who receive peritoneal dialysis.Although EPO has been included in the National List of Essential Drugs (NLED) for the treatment of anemia caused by end stage renal disease for maintaining the target hemoglobin but the cost of EPO is so expensive. Cost utility analysis is economic technique for assessing the efficiency of healthcare intervention measuring combined outcomes as the effectiveness, i.e., survival and quality of life in combination as quality adjusted life years (QALYs).This study is a benefit measure at the care giving level by using as a part of planning patient management program and at the policy level for decision making.